No time to lose: the current state of research in rapid-acting psychotherapeutics
Joshua A. Gordon, Nora D. Volkow, George F. Koob
Neuropsychopharmacology 2024 DOI: 10.1038/s41386-023-01627-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Intravenous ketamine is one of the few treatments that can resolve psychiatric and substance use disorder symptoms in minutes to hours, unlike most therapies that take weeks to work. |
Abstract
The vast majority of treatments for psychiatric and substance use disorders take weeks to work. Notable exceptions to this rule exist, with some treatments such as intravenous ketamine resolving symptoms in minutes to hours. Current research is focused on identifying novel approaches to rapid-acting psychotherapeutics. Promising results from studies of novel classes of drugs and innovative brain stimulation therapies are currently being studied through both clinical and pre-clinical research, as described here. Research focused on understanding neurobiological mechanisms, effective therapeutic context, and implementation approaches are needed to maximize the potential reach of these therapies.
Citations in the library
Cited by 3
- Trends in hallucinogen‐associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022 Addiction January 11, 2024
- Novel rapid treatment options for adolescent depression. Pharmacological Research March 1, 2024
- "I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke. Addiction Science & Clinical Practice July 21, 2025
Cites 17
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis American Journal of Psychiatry October 3, 2017
and 12 more in the library